EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences

Yangqingqing Zhou, Wunan Huang, Xinyue Hang, Yanlin He, Ruiyuan He, Chaosheng Gan

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-025-04834-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Yangqingqing Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, No.277 Yanta West Road, Xi'an, 710061, Shaanxi, China. Hauptthemen laut MEDLINE: Immunoconjugates, Cell Adhesion Molecules, Lung Neoplasms, Camptothecin. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 99 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Trophoblast cell-surface antigen 2 (TROP2) is a cell surface glycoprotein that plays a significant role in the self-renewal, proliferation, invasion and transformation of tumor cells, and is highly expressed in a variety of tumors. At present, TROP2 has become an important target for the research and development of Antibody-drug conjugates (ADCs) in the field of lung cancer. Although sacituzumab govitecan, datopotamab deruxtecan and sacituzumab tirumotecan are all TROP2-targeted ADCs, there are certain differences in their drug structures. These differences may have led to the distinctions in their anti-tumor activity and safety. This study aims to review the similarities and differences among these three drugs, with the expectation of providing some assistance for the selection of clinical medication. METHODS: The key words Sacituzumab govitecan/IMMU-132, Datopotamab deruxtecan/DS-1062a and Sacituzumab tirumotecan/SKB264 retrieved Medline/PubMed, Google Scholar, Web of Science and ScienceDirect databases until September 25, 2025. Articles about pharmacokinetics, pharmacodynamics, drug safety and other aspects were selected to systematically summarize. RESULTS: These three TROP2 ADCs have many similarities in terms of pharmacokinetics, pharmacodynamics and common treatment-related adverse events. However, there are some differences in the efficacy of combination with immunotherapy drugs and treatment-related adverse events over grade 3. CONCLUSION: There are differences in pharmacological effects, efficacy, and incidence of adverse events among sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan. For patients with EGFR-mutated progression after targeted therapy or driver gene negative advanced non-small cell lung cancer, the individualized optimization of TROP2 ADCs treatment can obtain the greatest benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesCell Adhesion MoleculesLung NeoplasmsCamptothecinCarcinoma, Non-Small-Cell LungAntibodies, Monoclonal, HumanizedAntigens, NeoplasmHumans

Stichwörter der Autor:innen

Antibody-drug conjugatesDatopotamab deruxtecanNon-small-cell lung cancerSacituzumab govitecanSacituzumab tirumotecanTrophoblast cell-surface antigen 2

Substanzen

sacituzumab govitecanImmunoconjugatesCell Adhesion MoleculesTACSTD2 protein, humanCamptothecinAntibodies, Monoclonal, HumanizedAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, No.277 Yanta West Road, Xi'an, 710061, Shaanxi, China.
  • Key Laboratory of Gynecologic Oncology Gansu Province, The First Hospital of Lanzhou University, Lanzhou, China.
  • Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta West Road, Yanta District, Xi'an, 710061, Shaanxi, China. gan19950607@163.com.

Zitieren

APA

Zhou, Y., Huang, W., Hang, X., He, Y., He, R., & Gan, C. (2025). Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04834-0

Vancouver

Zhou Y, Huang W, Hang X, He Y, He R, Gan C. Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04834-0

BibTeX
@article{Zhou2025,
  author = {Zhou, Yangqingqing and Huang, Wunan and Hang, Xinyue and He, Yanlin and He, Ruiyuan and Gan, Chaosheng},
  title = {Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-025-04834-0}
}
Kostenlos starten →